Supplementary Figure 12

CMC - PFS

Variable		N	Hazard ratio		р
delta CMC	Increase	23	•	Reference	
	Decrease	29	⊢■ ∹	0.51 (0.27, 0.97)	0.04
Study Cohort	A: Head & Neck	12	į.	Reference	
	B: Breast	10	· !	2.13 (0.86, 5.26)	0.10
	C: Ovarian	10	- ;■	1.30 (0.54, 3.14)	0.55
	D: Melanoma	9		0.12 (0.02, 0.68)	0.02
	E: Other	11	⊢ ■	0.53 (0.22, 1.29)	0.16
PD-L1 fraction		52	- ■ ; ·	0.40 (0.13, 1.22)	0.11
log(TMB)		52	⊢	1.02 (0.67, 1.54)	0.93

CMC - OS

Variable		N	Н	azard ratio			р
delta CMC	Increase	24				Reference	
	Decrease	29			ri.	0.57 (0.29, 1.12)	0.100
Study Cohort	A: Head & Neck	12			•	Reference	
	B: Breast	10		<u> </u>	-	0.59 (0.24, 1.48)	0.262
	C: Ovarian	10			-	0.25 (0.09, 0.66)	0.005
	D: Melanoma	10		——		0.09 (0.02, 0.43)	0.003
	E: Other	11			 ¦	0.34 (0.13, 0.86)	0.023
PD-L1 fraction		53		-	 ¦	0.29 (0.09, 0.94)	0.038
log(TMB)		53			-	1.21 (0.79, 1.86)	0.377

Supplementary Figure 12. Multivariate Cox analysis of change in cancer mutation concentration (CMC) from baseline to cycle 3 of pembrolizumab. Covariates include cohort, PD-L1 expression, and tumor mutation burden.